Jeffrey S. Weber, MD, PhD
Favorable long-term phase II results of the combination of dabrafenib (Tafinlar) plus trametinib (Mekinist) in patients with BRAF
V600-mutant melanoma were presented at the 2017 ASCO Annual Meeting, demonstrating that the regimen had 4-year and 5-year overall survival (OS) rates of 30% and 28%, respectively.1
during the 2017 ASCO Annual Meeting.
OncLive: Can you discuss the 5-year follow-up results with the dabrafenib/trametinib combination in melanoma presented at the 2017 ASCO Annual Meeting?
The gist of the presentation that I made was that our study was the longest-term follow-up with any BRAF/MEK inhibitory combination trial done. This was a randomized phase II portion of a larger phase I/II trial, part C, in which 50 or so patients per arm were randomized to get the BRAF/MEK inhibitor combination, dabrafenib/trametinib, at the standard dose of dabrafenib 150 mg twice daily by mouth and then trametinib at either 2 mg or 1 mg once daily by mouth versus the control arm of dabrafenib alone, which was then an FDA-approved treatment at the 150-mg daily standard dose.
... to read the full story